SK Biopharmaceuticals Co., Ltd. provided earnings guidance for the year 2021. For the year, the company expects over KRW 200 billion in revenue due to sales revenue growth of XCOPRI, milestone payment following the EMA's approval in EU, and installment method of revenue recognition of up-front payment from licensing out to Japan, and rising royalty revenue from solriamfetol. Approximately over 30% to 40% of this year's revenue is expected to come from sales revenue of XCOPRI.